Thomas Hoock Selected Research

2- ((2- (1H- pyrrolo(2,3- b)pyridin- 3- yl)pyrimidin- 4- yl)amino)- 2- methyl- N- (2,2,2- trifluoroethyl)butanamide

9/2015	Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
2/2015	A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Hoock Research Topics

Disease

1	Autoimmune Diseases (Autoimmune Disease) 09/2015
1	Headache (Headaches) 02/2015
1	Hypercholesterolemia 02/2015
1	Infections 02/2015
1	Nausea 02/2015
1	Rheumatoid Arthritis 02/2015

Drug/Important Bio-Agent (IBA)

2	2- ((2- (1H- pyrrolo(2,3- b)pyridin- 3- yl)pyrimidin- 4- yl)amino)- 2- methyl- N- (2,2,2- trifluoroethyl)butanamideIBA 09/2015 - 02/2015
1	Janus Kinase 3IBA 09/2015
1	Phosphotransferases (Kinase)IBA 09/2015
1	Tyrosine (L-Tyrosine)FDA Link 09/2015
1	LipidsIBA 02/2015
1	Alanine Transaminase (SGPT)IBA 02/2015
1	Transaminases (Aminotransferases)IBA 02/2015
1	VX (EDIM)IBA 02/2015

Therapy/Procedure

1	Therapeutics 09/2015